WEKO3
アイテム
Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients
http://hdl.handle.net/10295/00006225
http://hdl.handle.net/10295/000062253cf120a3-4ab1-4017-ad16-f29c0255977b
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2023-02-23 | |||||
タイトル | ||||||
タイトル | Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients | |||||
言語 | en | |||||
言語 | ||||||
言語 | eng | |||||
主題 | ||||||
主題Scheme | Other | |||||
主題 | everolimus | |||||
主題 | ||||||
主題Scheme | Other | |||||
主題 | polymorphism | |||||
主題 | ||||||
主題Scheme | Other | |||||
主題 | pregnane X-receptor | |||||
主題 | ||||||
主題Scheme | Other | |||||
主題 | P-glycoprotein | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
作成者 |
Yagishita, Hironobu
× Yagishita, Hironobu× Kagaya, Hideaki× Saito, Mitsuru× Numakura, Kazuyuki× Yamamoto, Ryohei× Sagehashi, Ryuichiro× Habuchi, Tomonori× Satoh, Shigeru× Miura, Masatomo |
|||||
内容記述 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The purpose of this study was to evaluate the effects of NR1I2 (7635G>A and 8055C>T) and ABCB1 (1236C>T, 2677G>T/A, and 3435C>T) genetic polymorphisms on everolimus pharmacokinetics in 98 Japanese renal transplant patients. On day 15 after everolimus administration, blood samples were collected just prior to and 1, 2, 3, 4, 6, 9, and 12 h after administration. The dose-adjusted area under the blood concentration-time curve (AUC(0-12)) of everolimus was significantly lower in patients with the NR1I2 8055C/C genotype than in those with other genotypes (p = 0.022) and was significantly higher in male patients than female patients (p = 0.045). Significant correlations between the dose-adjusted AUC(0-12) of everolimus and age (p = 0.001), aspartate transaminase (p = 0.001), and alanine transaminase (p = 0.005) were found. In multivariate analysis, aging (p = 0.008) and higher alanine transaminase levels (p = 0.032) were independently predictive of a higher dose-adjusted everolimus AUC(0-12). Aging and hepatic dysfunction in patients may need to be considered when evaluating dose reductions in everolimus. In renal transplant patients, management using everolimus blood concentrations after administration may be more important than analysis of NR1I2 8055C>T polymorphism before administration. | |||||
言語 | en | |||||
出版タイプ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
書誌情報 |
en : INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 巻 23, 号 19, 発行日 2022 |
|||||
収録物識別子 | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1422-0067 | |||||
出版者 | ||||||
出版者 | MDPI | |||||
関連情報 | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.3390/ijms231911742 | |||||
権利情報 | ||||||
権利情報 | © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |